Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Avouac

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Annals of the Rheumatic Diseases|July 26, 2008
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cellsJ H W Distler, Y Allanore, J Avouac, et al.
Arthritis and Rheumatism|January 1, 2009
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosisP Dieudé, M Guedj, J Wipff, et al.
Rheumatology (Oxford, England)|February 16, 2008
Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologistsP I Sidiropoulos, G Hatemi, I-H Song, et al.
Arthritis and Rheumatism|August 1, 2009
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosisP Dieudé, M Guedj, J Wipff, et al.
Annals of the Rheumatic Diseases|November 18, 2010
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research GroupJ Avouac, J Fransen, U A Walker, et al.
Arthritis and Rheumatism|October 31, 2009
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4P Dieudé, J Wipff, M Guedj, et al.
Annals of the Rheumatic Diseases|December 15, 2010
NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesisP Dieudé, M Guedj, J Wipff, et al.
Annals of the Rheumatic Diseases|January 17, 2009
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)O Kowal-Bielecka, R Landewé, J Avouac, et al.
Annals of the Rheumatic Diseases|October 30, 2008
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature researchJ Avouac, O Kowal-Bielecka, R Landewe, et al.
Arthritis and Rheumatism|September 8, 2011
Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotypeP Dieudé, M Bouaziz, M Guedj, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Annals of the Rheumatic Diseases|July 26, 2008
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cellsJ H W Distler, Y Allanore, J Avouac, et al.
Arthritis and Rheumatism|January 1, 2009
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosisP Dieudé, M Guedj, J Wipff, et al.
Rheumatology (Oxford, England)|February 16, 2008
Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologistsP I Sidiropoulos, G Hatemi, I-H Song, et al.
Arthritis and Rheumatism|August 1, 2009
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosisP Dieudé, M Guedj, J Wipff, et al.
Annals of the Rheumatic Diseases|November 18, 2010
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research GroupJ Avouac, J Fransen, U A Walker, et al.
Arthritis and Rheumatism|October 31, 2009
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4P Dieudé, J Wipff, M Guedj, et al.
Annals of the Rheumatic Diseases|December 15, 2010
NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesisP Dieudé, M Guedj, J Wipff, et al.
Annals of the Rheumatic Diseases|January 17, 2009
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)O Kowal-Bielecka, R Landewé, J Avouac, et al.
Annals of the Rheumatic Diseases|October 30, 2008
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature researchJ Avouac, O Kowal-Bielecka, R Landewe, et al.
Arthritis and Rheumatism|September 8, 2011
Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotypeP Dieudé, M Bouaziz, M Guedj, et al.
Pageof 4